[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,517,812
  • Shares Outstanding, K 60,905
  • Annual Sales, $ 0 K
  • Annual Income, $ -103,690 K
  • EBIT $ -116 M
  • EBITDA $ -116 M
  • 60-Month Beta 0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.79

Options Overview Details

View History
  • Implied Volatility 139.65% (+1.68%)
  • Historical Volatility 55.82%
  • IV Percentile 79%
  • IV Rank 53.07%
  • IV High 238.27% on 01/07/26
  • IV Low 28.13% on 09/09/25
  • Expected Move (DTE 31) 9.82 (24.77%)
  • Put/Call Vol Ratio 1.73
  • Today's Volume 109
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 2.93
  • Today's Open Interest 10,204
  • Open Int (30-Day) 12,953
  • Expected Range 29.81 to 49.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 1
  • High Estimate $-0.41
  • Low Estimate $-0.41
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) +16.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.78 +2.19%
on 05/18/26
48.15 -17.69%
on 04/20/26
-8.48 (-17.63%)
since 04/17/26
3-Month
25.29 +56.70%
on 02/20/26
48.53 -18.34%
on 04/17/26
+13.26 (+50.28%)
since 02/18/26
52-Week
14.78 +168.04%
on 01/06/26
48.53 -18.34%
on 04/17/26
+22.77 (+135.05%)
since 05/16/25

Most Recent Stories

More News
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Phase 1 data update for ELVN-001 expected mid-2026

ELVN : 39.63 (-4.14%)
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

BOULDER, Colo. , Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 39.63 (-4.14%)
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small...

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery...

ELVN : 39.63 (-4.14%)
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and...

ELVN : 39.63 (-4.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO....

See More

Key Turning Points

3rd Resistance Point 44.35
2nd Resistance Point 43.06
1st Resistance Point 41.35
Last Price 39.63
1st Support Level 38.35
2nd Support Level 37.06
3rd Support Level 35.35

See More

52-Week High 48.53
Last Price 39.63
Fibonacci 61.8% 35.64
Fibonacci 50% 31.66
Fibonacci 38.2% 27.68
52-Week Low 14.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.